





Does the Extent of Poorly Differentiated Areas in Thyroid carcinoma affect clinical outcomes? A Retrospective study

Priyanka Singh; Anish Cherian; Shawn Thomas; Nirmal Daniel; K. Reka; Supriya Sen; Deepak Abraham; MJ Paul


Christian Medical College, Vellore, Tamil Nadu, India

Introduction	Material and methods
<ul style="list-style-type: none"> ➤ PDTC accounts for 2-15% of thyroid carcinomas ➤ Criteria for histologic diagnosis – evolving over time. Currently based on The Turin criteria (2006) ➤ Does not include percentage of poorly differentiated area ➤ Limited literature on patient outcomes based on the percentage of poorly differentiated areas (PDA) in histopathology ➤ Therefore, we conducted this study to determine if the percentage of PDA affects patient outcomes 	<ul style="list-style-type: none"> ➤ Retrospective, single-institution observational study (January 2006 to December 2021) ➤ Histopathology reported Poorly Differentiated Thyroid carcinoma or reported as Areas of Poorly Differentiated Thyroid carcinoma. ➤ The cohort was divided into groups based on the percentage of poorly differentiated areas; PDA: ≤10%, PDTC: 11-100%. Groups were then compared for outcomes ➤ Software SPSS statistic Version:26 has been used for statistics

Results



Comparison of PDA and PDTC	PDA(n=8)	PDTC(n=47)	
Demographic profile	n(%)	n(%)	P value
Age >55	3(37.5)	26(55.3)	0.70
M:F	1:7	1:3	0.36
Type of surgery			
TT	6(75)	31(66)	0.78
TT+LND	2(25)	14(29.8)	
Excision of recurrent lesion	0	16(34)	
Sternotomy	0	2(4.3)	
Laryngectomy/tracheal resection	0	4(8.5)	0.39
Metastasectomy	0	7(14.9)	0.57
Stage 4 disease	1(12.5)	13(27)	0.40
Tumor size>4cm	4(50)	37(79)	0.22
Intraoperative infiltration	0	17	0.04
ETE	0	16(34)	0.05
LVI	1(12.5)	39(83)	<0.01
Adjuvant treatment			
EBRT to Neck	0	9(19.1)	0.32
EBRT to metastatic site	1(12.5)	9(19.1)	0.18
Outcomes			
Local recurrence	1(12.5)	5(10.6)	0.80
Systemic metastasis	3(37.5)	25(53.2)	0.40
Survival variables			
Deceased	1(12.6)	4(6.4)	0.46
5-yr Overall survival	100%	92.4%	0.37
10-yr overall survival	80.5%	80.8%	



Discussion	
This Study	Literature Review
<ul style="list-style-type: none"> ➤ Frequency: 2.3% ➤ >10% Group showed more aggressive features such as ETE, LVI, and intraoperative infiltration: statistically significant ➤ Number of tumors greater than 4cm, stage 4 disease, Complex surgery and decrease RFS and DFS seen in >10% group ➤ Similar OS ➤ ≤10% group: 37.5% metastasis, 12.5% LR, 12.5% succumbed to disease ➤ Hence presence of minor component affect prognosis 	<p>Incidence : 1to15%; Jr.EMS et.al</p> <p>Similar to Tanaka et.al, Panchangam et.al, dettmer et.al</p> <p>Ibrahimasic et.al, Volante et.al</p> <p>Similar to Raouef bichoo et.al</p>

Conclusion

- PDTC accounted for 2.3% of thyroid carcinoma in this cohort.
- **Even presence of minor PDA, can affect prognosis.** Hence patients with any evidence of PDA in histopathology should be treated aggressively.
- **With percentage increase, significantly more aggressive features-LVI, ETE and Local infiltrations were seen; However, this did not affect rates of local recurrence, systemic metastasis and survival.**
- Survival rates in our cohort were better than reported in literature; however, this is limited by lack of follow-up data.